PL2094254T3 - Leczenie kacheksji - Google Patents

Leczenie kacheksji

Info

Publication number: PL2094254T3
Authority: PL; Poland
Prior art keywords: cachexia; treatment; prevention; receptors; tertatolol
Prior art date: 2006-12-05

Application number

PL07824794T

Other languages

English (en)

Inventor

David Cavalla

Original Assignee

Actimed Therapeutics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-05

Filing date

2007-12-05

Publication date

2011-12-30

2007-12-05 Application filed by Actimed Therapeutics Ltd filed Critical Actimed Therapeutics Ltd

2011-12-30 Publication of PL2094254T3 publication Critical patent/PL2094254T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Virology (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Nutrition Science (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)

PL07824794T 2006-12-05 2007-12-05 Leczenie kacheksji PL2094254T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0624282.0A GB0624282D0 (en)	2006-12-05	2006-12-05	Treatment of cachexia
EP07824794A EP2094254B1 (en)	2006-12-05	2007-12-05	Treatment of cachexia
PCT/GB2007/004644 WO2008068477A1 (en)	2006-12-05	2007-12-05	Treatment of cachexia

Publications (1)

Publication Number	Publication Date
PL2094254T3 true PL2094254T3 (pl)	2011-12-30

Family

ID=37671884

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07824794T PL2094254T3 (pl)	2006-12-05	2007-12-05	Leczenie kacheksji

Country Status (16)

Country	Link
US (1)	US8716325B2 (pl)
EP (2)	EP2094254B1 (pl)
JP (1)	JP5166437B2 (pl)
CN (1)	CN101610760B (pl)
AT (1)	ATE513543T1 (pl)
AU (1)	AU2007330607B2 (pl)
BR (1)	BRPI0720114A8 (pl)
CA (1)	CA2671622C (pl)
DK (1)	DK2094254T3 (pl)
ES (1)	ES2395244T3 (pl)
GB (1)	GB0624282D0 (pl)
PL (1)	PL2094254T3 (pl)
PT (1)	PT2094254E (pl)
RU (1)	RU2485950C2 (pl)
WO (1)	WO2008068477A1 (pl)
ZA (1)	ZA200904704B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0907350D0 (en) *	2009-04-29	2009-06-10	Myotec Therapeutics Ltd	Methods
EP2877247A1 (en) *	2012-07-25	2015-06-03	Psioxus Therapeutics Limited	Use of s-pindolol for treating cachexia and sarcopenia
ES2698363T3 (es)	2013-03-14	2019-02-04	Actimed Therapeutics Ltd	Composiciones de oxprenolol para tratar el cáncer
EP3419610A4 (en)	2016-02-26	2019-10-16	Actimed Therapeutics Ltd	S-ENANTIOMER ENHANCED COMPOSITIONS OF BETA LOAD FOR THE TREATMENT OF MUSCLE WEAKNESSES
GB2593902B (en) *	2020-04-07	2022-04-13	Actimed Therapeutics Ltd	Salt of a pharmaceutical compound
GB202114564D0 (en)	2021-10-12	2021-11-24	Actimed Therapeutics Ltd	Oral formulation
WO2025222169A1 (en)	2024-04-19	2025-10-23	Faraday Pharmaceuticals, Inc.	S-oxprenolol for preserving muscle mass, bone density, and cardiac function in weight loss treatments

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5541188A (en) *	1987-09-15	1996-07-30	The Rowett Research Institute	Therapeutic applications of beta-adrenergic agonists
CA1337432C (en)	1988-03-23	1995-10-24	Raymond M. Xhonneux	Method of lowering the blood pressure
US6545040B1 (en) *	1988-03-23	2003-04-08	Janssen Pharmaceutica N.V.	Method of lowering the blood pressure
CA2025398A1 (en)	1989-09-20	1992-03-15	Timothy Gerard Dinan	Diagnosis and treatment of a disorder of the gastrointestinal tract
US5120791A (en)	1990-07-27	1992-06-09	Lisco, Inc.	Golf ball cover compositions
US7417038B1 (en)	1998-10-15	2008-08-26	Imperial Innovations Limited	Methods of treating cachexia
CZ20022410A3 (cs) *	2000-01-31	2003-08-13	Pfizer Products Inc.	Benzoanelované heterocyklylové deriváty nikotinamidu užitečné jako selektivní inhibitory isozymů PDE4
AR030414A1 (es) *	2000-04-03	2003-08-20	Astrazeneca Ab	Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
ATE409475T1 (de) *	2001-02-20	2008-10-15	Dinan Timothy Gerard	Behandlung von fibromyalgie mit pindolol
US6670140B2 (en) *	2001-03-06	2003-12-30	The Procter & Gamble Company	Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
JP2008513430A (ja) *	2004-09-17	2008-05-01	ニューロキュアリミテッド	月経前症候群および月経前不快気分障害の処置のためのピンドロール
JP2008514612A (ja)	2004-09-23	2008-05-08	ミシャロウ、アレクサンダー	対抗適応を誘発することにより神経伝達物質系を調節する方法
WO2006102476A2 (en) *	2005-03-21	2006-09-28	Vicus Therapeutics Spe 1, Llc	Compositions and methods for ameliorating cachexia
JP2009526087A (ja) *	2005-12-22	2009-07-16	アナボレックス，インコーポレイテッド	悪液質の予防および処置のための組成物および方法
JP2009528289A (ja)	2006-02-27	2009-08-06	ミシャロウ、アレクサンダー	対抗適応を誘発することにより神経伝達物質系を調節する方法
AU2007316613B2 (en)	2006-11-09	2013-11-28	Boehringer Ingelheim International Gmbh	Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions
AU2008240379B2 (en)	2007-04-24	2012-10-04	Acacia Pharma Limited	Drug combination of beta 2 agonist and a progestin for the treatment of muscle loss
WO2009111648A1 (en)	2008-03-05	2009-09-11	Vicus Therapeutics, Llc	Compositions and methods for mucositis and oncology therapies

2006
- 2006-12-05 GB GBGB0624282.0A patent/GB0624282D0/en not_active Ceased
2007
- 2007-12-05 WO PCT/GB2007/004644 patent/WO2008068477A1/en not_active Ceased
- 2007-12-05 CN CN2007800446415A patent/CN101610760B/zh active Active
- 2007-12-05 US US12/312,756 patent/US8716325B2/en active Active
- 2007-12-05 CA CA2671622A patent/CA2671622C/en active Active
- 2007-12-05 JP JP2009539801A patent/JP5166437B2/ja active Active
- 2007-12-05 PT PT07824794T patent/PT2094254E/pt unknown
- 2007-12-05 PL PL07824794T patent/PL2094254T3/pl unknown
- 2007-12-05 ES ES07824794T patent/ES2395244T3/es active Active
- 2007-12-05 AT AT07824794T patent/ATE513543T1/de active
- 2007-12-05 RU RU2009125548/15A patent/RU2485950C2/ru active
- 2007-12-05 BR BRPI0720114A patent/BRPI0720114A8/pt not_active Application Discontinuation
- 2007-12-05 AU AU2007330607A patent/AU2007330607B2/en active Active
- 2007-12-05 DK DK07824794.7T patent/DK2094254T3/da active
- 2007-12-05 EP EP07824794A patent/EP2094254B1/en active Active
- 2007-12-05 EP EP11001660.7A patent/EP2359822B1/en active Active
2009
- 2009-07-03 ZA ZA200904704A patent/ZA200904704B/xx unknown

Also Published As

Publication number	Publication date
JP2010511685A (ja)	2010-04-15
DK2094254T3 (da)	2011-10-03
CN101610760A (zh)	2009-12-23
JP5166437B2 (ja)	2013-03-21
ATE513543T1 (de)	2011-07-15
PT2094254E (pt)	2011-09-19
GB0624282D0 (en)	2007-01-10
CN101610760B (zh)	2012-09-26
CA2671622C (en)	2015-01-27
ES2395244T3 (es)	2013-02-11
US20100292270A1 (en)	2010-11-18
AU2007330607B2 (en)	2013-02-07
EP2094254B1 (en)	2011-06-22
US8716325B2 (en)	2014-05-06
BRPI0720114A8 (pt)	2016-01-19
BRPI0720114A2 (pt)	2014-04-15
AU2007330607A1 (en)	2008-06-12
WO2008068477A1 (en)	2008-06-12
ZA200904704B (en)	2010-05-26
RU2009125548A (ru)	2011-01-20
EP2359822B1 (en)	2016-08-03
RU2485950C2 (ru)	2013-06-27
CA2671622A1 (en)	2008-06-12
EP2094254A1 (en)	2009-09-02
EP2359822A1 (en)	2011-08-24

Publication	Publication Date	Title
ZA200904704B (en)	2010-05-26	Treatment of cachexia
MX2009009537A (es)	2009-09-16	Nanoparticula que comprende rapamicina y albumina como agente anticancer.
AP2405A (en)	2012-05-02	Cannabinoid active pharmaceutical ingredient for improved dosage forms.
NO20090623L (no)	2009-03-20	Forbindelser for behandling av proliferative lidelser
UA98839C2 (en)	2012-06-25	N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
MX2010004450A (es)	2010-05-05	Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
PL1979355T3 (pl)	2011-04-29	Pochodne spiro imidazoli jako modulatory PPAR
WO2008022024A3 (en)	2008-05-22	Imidazole amines as inhibitors of beta-secretase
TNSN08284A1 (en)	2009-10-30	Masking the taste of powders
WO2009050136A3 (en)	2009-07-02	Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
WO2009071689A3 (de)	2009-07-23	5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
MX2007010560A (es)	2008-02-21	Roflumilast para el tratamiento de diabetes mellitus.
WO2008075201A3 (en)	2009-01-29	Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection
TW200740429A (en)	2007-11-01	Methods and dosage forms for reducing side effects of carbamate compounds
WO2007075825A3 (en)	2007-08-16	Lipophilic anticancer drug compounds
UA106200C2 (uk)	2014-08-11	Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
WO2008087329A3 (fr)	2008-11-27	Nouveau médicament pour le traitement d'un cancer gastrique
WO2007104933A8 (en)	2008-09-18	Chemical compounds
MY150776A (en)	2014-02-28	Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria
WO2007011958A3 (en)	2007-04-12	Intraoral dosage forms of glucagon
신영석	2006	On the appropriate use of health services
CL2007002797A1 (es)	2008-04-18	Composicion terapeutica que comprende un anticuerpo contra el receptor del egf, interferon y excipientes adecuados para su administracion por via intravenosa.
WO2008005806A3 (en)	2008-05-15	Therapeutic methods, compositions, and compounds
MY150436A (en)	2014-01-30	1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof
MX2007007183A (es)	2008-01-14	Aminas, combinacion de aminas y vanadio y sales de amina y vanadio para el tratamiento o prevencion de dislipidemia.